Luca Neri, MD, PhD

Senior Director, Global Operational Applied Artificial Intelligence and GenAI

Luca Neri

Dr. Neri earned his MD and PhD in Occupational and Environmental Medicine from the School of Medicine at the University of Milan. In 2005, he joined the Saint Louis University Center for Out-comes Research (SLUCOR) in St. Louis, Missouri, USA, as an epidemiologist and outcomes research scientist. During his tenure, he also served as an Adjunct Instructor of Health Management and Policy at SLUCOR until 2013. In January 2010, he also joined the Department of Clinical Science and Community Health at the University of Milan. 

Dr. Neri’s research has spanned a wide range of therapeutic areas. He has collaborated with academic institutions and commercial organizations to develop innovative research, address complex investigative questions, and solve challenges in research design. 

Dr. Neri joined Fresenius Medical Care as a medical data scientist in 2016. He currently leads the Operational Applied Artificial Intelligence and Generative AI (GenAI) department at the Renal Re-search Institute. 

He has authored over 100 original papers in international, peer-reviewed scientific journals, primarily focusing on outcomes research, epidemiology and artificial intelligence in medicine. 

His team develops cutting-edge AI solutions to assist healthcare professionals in optimizing daily clinical tasks and improving patient outcomes.

Contact Information:

Recent Articles by Luca Neri, MD, PhD

  • Current opinion in nephrology and hypertension
    November 7, 2025
    Artificial intelligence in kidney disease and dialysis: from data mining to clinical impact
    Luca Neri, Hanjie Zhang, Len A Usvyat
    PURPOSE OF REVIEWArtificial intelligence (AI) and machine learning (ML) are rapidly transforming healthcare, but their adoption in nephrology and dialysis remains relatively limited.SUMMARYAI in nephrology shows promise for personalized care and cost reduction, as demonstrated by tools like the Anemia Control Model. Yet, broad adoption requires rigorous validation, seamless workflow integration, regulatory clearance, and clinician trust. Future opportunities include digital twins, large language models, and multiomics integration, with AI poised to enhance both patient outcomes and system performance.RECENT FINDINGSThis review highlights key applications of AI in kidney disease, including prognostic modeling, imaging, personalized anemia and fluid management, patient engagement, and research acceleration. While numerous studies demonstrate improved prediction accuracy and clinical insights, translation into routine practice is rare. Examples such as the Anemia Control Model (ACM) demonstrate that AI can simultaneously improve clinical outcomes and reduce costs, though widespread adoption will require rigorous validation, seamless integration into clinical workflows, regulatory approval, and above all, clinician trust.